Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

Not specified

Study Completion Date

July 31, 2000

Conditions
Sarcoma, KaposiHIV Infections
Interventions
DRUG

Etoposide

Trial Locations (20)

10019

Saint Clare's Hosp and Health Ctr, New York

10029

Mount Sinai Med Ctr, New York

11373

City Hosp Ctr at Elmhurst / Mount Sinai Hosp, Elmhurst

14215

SUNY / Erie County Med Ctr at Buffalo, Buffalo

29169

Julio Arroyo, West Columbia

35294

Univ of Alabama at Birmingham, Birmingham

60611

Northwestern Univ Med School, Chicago

80262

Denver Dept of Health and Hosps, Denver

Univ of Colorado Health Sciences Ctr, Denver

100323784

Columbia Presbyterian Med Ctr, New York

122083479

Adirondack Med Ctr at Saranac Lake, Albany

Albany Med College / Division of HIV Medicine A158, Albany

Mid - Hudson Care Ctr, Albany

331361013

Univ of Miami School of Medicine, Miami

462025250

Indiana Univ Hosp, Indianapolis

900331079

K Norris Cancer Hosp / Los Angeles County - USC Med Ctr, Los Angeles

Univ of Southern California / LA County USC Med Ctr, Los Angeles

941102859

San Francisco Gen Hosp, San Francisco

065102483

Yale Univ / New Haven, New Haven

02118

Boston Med Ctr, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Bristol-Myers Squibb

INDUSTRY

NCT00000807 - Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy | Biotech Hunter | Biotech Hunter